BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 2.19B +27.5% |
| Revenue (ttm) | 885.72M +75.9% |
| Net Income | -457.98M |
| EPS | -2.10 |
| Shares Out | 254.16M |
| PE Ratio | n/a |
| Forward PE | 29.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,164,438 |
| Open | 8.96 |
| Previous Close | 8.90 |
| Day's Range | 8.56 - 8.99 |
| 52-Week Range | 6.00 - 11.31 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 21.11 (+144.9%) |
| Earnings Date | May 6, 2026 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BCRX stock is "Strong Buy." The 12-month stock price target is $21.11, which is an increase of 144.90% from the latest price.
News
BioCryst price target raised to $28 from $25 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $28 from $25 and keeps an Outperform rating on the shares. Orladeyo posted a typical seasonal Q1
BioCryst reports Q1 EPS ($2.98), consensus 11c
Reports Q1 revenue $156.41M, consensus $151.12M. BioCryst (BCRX) recorded a GAAP operating loss of $701.6M for the first quarter, primarily reflecting the special, non-cash charge related to acquired ...
BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 17% revenue growth and a 25% rise in non-GAAP operating profit, driven by strong ORLADEYO demand and successful Astria integration. Guidance for 2026 remains unchanged despite a pediatric manufacturing delay, with robust liquidity and pipeline progress.
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted si...
BioCryst enters navenibart license agreement with Neopharmed Gentili
BioCryst (BCRX) announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. I...
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst to Report First Quarter 2026 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on...
BioCryst price target raised to $14 from $13 at RBC Capital
RBC Capital raised the firm’s price target on BioCryst (BCRX) to $14 from $13 and keeps an Outperform rating on the shares as part of the firm’s broader research note
BioCryst appoints Sandeep Menon as chief research and development officer
BioCryst (BCRX) announced the appointment of Sandeep Menon as chief research and development officer. Menon joins BioCryst from Alnylam (ALNY), where he served as chief development officer, overseeing...
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —
BioCryst reports inducement grants under Nasdaq listing rule
BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units covering an aggregate of 65,850 shar...
BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Revenue growth is driven by strong U.S. performance, expanding prescriber base, and high patient retention among super-responders. The pipeline is advancing with navenibart and a KLK5 inhibitor, while pediatric and community market penetration continues to rise.
BioCryst price target raised to $22 from $21 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on BioCryst (BCRX) to $22 from $21 and keeps an Outperform rating on the shares. While the company preannounced Q4 results
BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered record 2025 revenue and profitability, driven by ORLADEYO growth and strategic portfolio expansion. 2026 guidance projects continued double-digit revenue growth, with new pediatric and injectable HAE therapies advancing and strong U.S. market focus.
BioCryst reports Q4 EPS $1.12 vs (13c) last year
Reports Q4 revenue $406.555M vs $131.534M last year. “2025 was fundamentally transformative for BioCryst (BCRX). We achieved full-year profitability for the first time in the company’s history, driven...
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on...
BioCryst resumed with an Outperform at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner resumed coverage of BioCryst (BCRX) with an Outperform rating and $17 price target The strategic move with the Astria Therapeutics (ATXS) acquisition positions...
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Car...
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedem...
BioCryst reports inducement grants under Nasdaq listing rule
BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted 24 newly-hired employees stock options to purchase an aggregate of 251,150 shares, an...
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on ...
BioCryst completes acquisition of Astria Therapeutics
BioCryst Pharmaceuticals (BCRX) announced that it has completed its acquisition of Astria Therapeutics (ATXS) initially announced on October 14, 2025. The transaction strengthens its position as a lea...
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initia...